| 马 莹,王 晨.不同剂量司库奇尤单抗治疗中重度银屑病疗效分析[J].中国烧伤创疡杂志,2023,(5):413~416. |
| DOI： |
| 中文关键词: 司库奇尤单抗 银屑病 银屑病面积和严重程度指数 免疫功能 炎症反应 |
| 英文关键词:Secukinumab Psoriasis Psoriasis area and severity index Immune function Inflammatory response |
| 基金项目: |
|
| 摘要点击次数: 1371 |
| 全文下载次数: 4236 |
| 中文摘要: |
| 【摘要】 目的 分析探讨不同剂量司库奇尤单抗治疗中重度银屑病的临床疗效。方法 选取 2020 年 1 月至2021 年 5 月南阳市中心医院收治的 104 例中重度银屑病患者作为研究对象, 按照不同用药剂量将其分为高剂量组(52 例) 和低剂量组 (52 例)。高剂量组患者皮下注射司库奇尤单抗注射液 300 mg / 次, 低剂量组患者皮下注射司库奇尤单抗注射液 150 mg / 次, 对比观察两组患者银屑病面积和严重程度指数 (PASI) 评分、临床症状评分?血清炎症因子及免疫相关指标水平与不良反应发生情况。结果 治疗结束后, 高剂量组患者 PASI 评分明显低于低剂量组 (t = 8.228, P < 0.001), 寻常型银屑病主症量表各维度评分均明显低于低剂量组 ( t = 2.525、2.447?3.759, P = 0.013、0.016、0.001), 血清白细胞介素 ( IL) -10 及 CD4+ 水平均明显高于低剂量组 ( t = 4.059?3.735, P 均 < 0.001), 血清 IL-17 及辅助性 T 细胞 17 (Th17) 水平均明显低于低剂量组 ( t = 4.245、6.295, P均 < 0.001)。治疗期间, 高剂量组患者不良反应发生率为 30.77% , 与低剂量组患者的不良反应发生率 17.31%无明显差异 (χ2= 2.580, P = 0.108)。结论 与低剂量司库奇尤单抗相比, 高剂量司库奇尤单抗更能明显提高中重度银屑病患者免疫功能, 减轻机体炎症反应, 缓解银屑病症状, 且并未明显增加不良反应发生风险。 |
| 英文摘要: |
| 【Abstract】 Objective To study the clinical efficacy of Secukinumab at different dosages in treating moderate-to-severe psoriasis. Methods 104 patients with moderate-to-severe psoriasis admitted into Nanyang Central Hospital between January 2020 and May 2021 were enrolled as research subjects, and divided into high dosage group (n = 52) and low dosage group(n = 52) based on different dosages they received. Patients in the high dosage group were given the subcutaneous injection of Secukinumab Injection at 300 mg / time, while patients were given the subcutaneous injection of Secukinumab Injection at 150 mg / time in the low dosage group. The psoriasis area and severity index ( PASI) score, score of clinical symptoms scale, levels of serum inflammatory factors and immune-related indexes, and the occurrence of adverse reactions of patients were compared between the two groups. Results At the end of treatment, compared with the low dosage group, the PSAI score of patients was obviously lower (t = 8.228, P < 0.001), the scores of main symptoms scale of psoriasis vulgaris were markedly lower (t = 2.525, 2.447 and 3.759, P = 0.013, 0.016 and 0.001), the levels of serum interleukin ( IL) -10 and CD4+ were obviously higher (t = 4.059 and 3.735, both P < 0.001), and the levels of serum IL-17 and T helper cell17 (Th17) were significantly lower (t = 4.245 and 6.295, both P < 0.001) in the high dosage group. During the course of treatment, the incidence of adverse reactions of patients was 30.77% in the high dosage group, which showed no significant difference compared with the corresponding 17.31% in the low dosage group ( χ2= 2.580, P = 0.108 ) .Conclusion Compared with the low dosage application of Secukinumab, the high dosage application of Secukinumab can significantly improve the immune functions of patients with moderate-to-severer psoriasis, and alleviate their inflammatory responses and proriasis symptoms, without increasing the risk of adverse reactions. |
|
|
|
|
